KB-R7785

KB-R7785 is a matrix metalloproteinase (MMP) inhibitor, which improves insulin sensitivity by inhibiting TNF-α production. KB-R7785 can be used for diabetes research. KB-R7785 has a protective efficacy against focal cerebral ischemia[1][2].

Product Specifications

CAS Number

[168158-16-5]

UNSPSC

12352005

Target

MMP

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/kb-r7785.html

Purity

99.90

Solubility

DMSO : 20 mg/mL (ultrasonic)

Smiles

ONC([C@@H](C)[C@@H](CC(C)C)C(N[C@@H](C1=CC=CC=C1)C(NC)=O)=O)=O

Molecular Formula

C18H27N3O4

Molecular Weight

349.42

References & Citations

[1]Morimoto Y, et al. KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production. Life Sci. 1997;61 (8) :795-803.|[2]Jiang X, et al. Matrix metalloproteinase inhibitor KB-R7785 attenuates brain damage resulting from permanent focal cerebral ischemia in mice. Neurosci Lett. 2001 Jun 1;305 (1) :41-4.